Literature DB >> 26035808

Relationship Between Age, Gender, and Race in Patients Presenting With Myasthenia Gravis With Only Ocular Manifestations.

Jason H Peragallo1, Elena Bitrian, Mark J Kupersmith, Fritz Zimprich, Thomas J Whittaker, Michael S Lee, Beau B Bruce.   

Abstract

BACKGROUND: The demographic associations among patients presenting with myasthenia gravis with only ocular manifestations (OMG) is not clear.
METHODS: In this 5-center case series, we collected the race, gender, and age at diagnosis of patients diagnosed with myasthenia gravis who had no signs or symptoms of generalized myasthenia gravis (GMG). An a priori sample size calculation determined that 140 patients were required to accept that there was a ≤10-year difference in mean age (equivalence testing: power 90%, α = 0.05). Robust Bayesian analysis and linear regression were applied to evaluate whether age differed by gender or race.
RESULTS: Of 433 patients included, 258 (60%) were men. Mean age among men was 57 years (SD = 19) and 52 years (SD = 21) among women. The 95% credible interval (CI) (Bayesian equivalent of confidence interval) was 0.8-8.7 years for mean age, and there was a 99.6% probability that the mean difference in age between sexes was <10 years. Race was documented in 376 (68 [18%] non-Caucasian). Caucasians were 17.3 years older than non-Caucasians at diagnosis (95% CI, 12.2-22.3 y; P < 0.001) controlling for gender. There was no additive interaction of gender and race (P = 0.74). There was a bimodal distribution for women peaking around 30 and 60 years. Men had a left skewed unimodal age distribution peaking at age 70.
CONCLUSIONS: The distribution of age at presentation in patients with OMG is different between men and women, similar to GMG. Non-Caucasian patients tend to develop OMG at a younger age.

Entities:  

Mesh:

Year:  2016        PMID: 26035808     DOI: 10.1097/WNO.0000000000000276

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  3 in total

1.  [Clinical and paraclinical profile of autoimmune myasthenia gravis in Ouagadougou, Burkina Faso].

Authors:  Djingri Labodi Lompo; Nagaonlé Éric Some; Adja Mariam Ouedraogo; Rodrigue P Yonli; Ousséini Diallo; Christian Napon; Athanase Millogo; Jean Kabore
Journal:  Med Trop Sante Int       Date:  2021-11-11

Review 2.  The epidemiology of myasthenia gravis.

Authors:  Ana-Maria Bubuioc; Aigerim Kudebayeva; Saule Turuspekova; Vitalie Lisnic; Maurizio Angelo Leone
Journal:  J Med Life       Date:  2021 Jan-Mar

3.  Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study.

Authors:  Andreas Totzeck; Elakiya Ramakrishnan; Melina Schlag; Benjamin Stolte; Kathrin Kizina; Saskia Bolz; Andreas Thimm; Mark Stettner; Julian R Marchesi; Jan Buer; Christoph Kleinschnitz; Hedda Luise Verhasselt; Tim Hagenacker
Journal:  Ther Adv Neurol Disord       Date:  2021-08-11       Impact factor: 6.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.